Fig. 2From: A phase 2b/3b MenACWY-TT study of long-term antibody persistence after primary vaccination and immunogenicity and safety of a booster dose in individuals aged 11 through 55 yearsSubject disposition in the antibody persistence phase* and the booster phase.MenACWY meningococcal A, C, W, Y, PS polysaccharide, TT tetanus toxoid*Years 7–10 after the primary vaccination†Completed all visits, n = 203Back to article page